Legend Biotech price target raised to $92 from $90 at Barclays

Barclays analyst Gena Wang raised the firm’s price target on Legend Biotech to $92 from $90 and keeps an Overweight rating on the shares. The company’s Q2 revenue beat by a wide margin, the analyst tells investors in a research note. The firm continues to see significant commercial opportunity for Legend given its “best-in-class” Carvykti asset, large patient population, and continued improvement in manufacturing capacity.